Evidence map›Paper›PMID 28780072›Full record

ReviewGastroenterology2018

Presentation and Epidemiology of Gastroesophageal Reflux Disease.

Joel E Richter, Joel H Rubenstein

2 registry-linked trialsOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 293 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
293citing papers in PubMed, 12 pooled it
30.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05818072 narecruitingnot on this mapstarted 2023, after this paper: background citation

The Prevalence, Risk Factors and Optimal Biopsy Protocol of Barrett's Esophagus in Taiwan - A Prospective Randomized Study

TypeinterventionalSponsorE-DA HospitalRan2023 to 2026Enrolled165ConditionsBarrett's Esophagus, Intestinal MetaplasiaArmsOne biopsy, Three biopsy, Seattle protocol, Endoscopy
NCT06778395 phase4completednot on this mapstarted 2024, after this paper: background citation

Therapeutic Effect of Vonoprazan Versus Dexlansoprazole in Treatment of Gastroesophageal Reflux Disease in Egyptian Patients: A Prospective Comparative Study

TypeinterventionalSponsorAyman Magd Eldin Mohammad SadekRan2024 to 2024Enrolled136ConditionsVonoprazan, Proton Pump Inhibitor, Gastroesophageal Reflux DiseaseArmsDexlansoprazole 60 mg, Vonoprazan 20 mg bid
3 · Its place in the literature

Who cites it

293 citing papers in PubMed, 12 syntheses or guidelines pooled it, 674 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Is the Addition of Sublingual Melatonin to Omeprazole Superior to Omeprazole Alone in the Management of Gastroesophageal Reflux Disease Symptoms: A Clinical Trial.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023
    Trial
  18. Trial
  19. Trial
  20. Article

233 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Joel E RichterJoy McCann Culverhouse Center for Swallowing Disorders, Division of Digestive Diseases & Nutrition, University of South Florida College of Medicine, Tampa, Florida. Electronic address: Jrichte1@health.usf.edu.
Joel H RubensteinVeterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan; Barrett's Esophagus Program, Division of Gastroenterology & Hepatology, University of Michigan Medical School, Ann Arbor, Michigan.
Florida College · USUniversity of Michigan–Ann Arbor · US

Funding

Controlling Esophageal Cancer: A Collaborative Modeling ApproachU01CA199336 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HUR, CHIN, INADOMI, JOHN MATTHEW · 2015 to 2019
$5.9M
Validation and Extension of the Michigan Barretts Esophagus pREdiction Tool (M-BERET)I01CX000899 · VA · VETERANS HEALTH ADMINISTRATION · PI RUBENSTEIN, JOEL H · 2015 to 2018
–
CSRD VA I01 CX000899NCI NIH HHS U01 CA199336
6 · The paper itself

Abstract

Gastroesophageal reflux disease (GERD) is the most prevalent gastrointestinal disorder in the United States, and leads to substantial morbidity, though associated mortality is rare. The prevalence of GERD symptoms appeared to increase until 1999. Risk factors for complications of GERD include advanced age, male sex, white race, abdominal obesity, and tobacco use. Most patients with GERD present with heartburn and effortless regurgitation. Coexistent dysphagia is considered an alarm symptom, prompting evaluation. There is substantial overlap between symptoms of GERD and those of eosinophilic esophagitis, functional dyspepsia, and gastroparesis, posing a challenge for patient management.

Indexed as

Age FactorsBiopsyDiagnosis, DifferentialDyspepsiaEosinophilic EsophagitisEsophageal NeoplasmsEsophagitis, PepticEsophagoscopyFemaleGastroesophageal RefluxGastrointestinal HemorrhageGastroparesisHeartburnHumansMaleObesityBarrett’s EsophagusErosive EsophagitisEsophageal Stricture

Identifiers

PMID28780072
PMCPMC5797499
OpenAlexW2744700122

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.